33 completed. 33 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 33 | Completed 33 |
| Phase 2 | 9 | Completed 9 |
Follow Peripheral T-Cell Lymphoma: new trials by email Literature Review of Peripheral T-Cell Lymphoma trials Research Report on Peripheral T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
| Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Romidepsin, Busulfan, Fludarabine - Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 23 | 2017-12-08 | 2025-09-19 |
| Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients Chidamide, cyclophosphamide, adriacin - Peripheral T-cell Lymphoma | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 30 | 2016-08-11 | 2019-07-24 |
| Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma Selinexor, ICE Chemotherapy - Peripheral T-cell Lymphoma | Phase 1 | Completed | National Cancer Centre, Singapore | 11 | 2016-07-01 | 2021-04-28 |
| A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Temsirolimus, Etoposide, Cyclophosphamide - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 16 | 2015-07-03 | 2023-07-27 |
| ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas ALRN-6924 - Solid Tumor, Lymphoma | Phase 1 / Phase 2 | Completed | Aileron Therapeutics, Inc. | 142 | 2014-10-01 | 2026-01-13 |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Carfilzomib, Belinostat - Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Massachusetts General Hospital | 19 | 2014-10-01 | 2018-01-25 |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Pralatrexate injection, Vitamin B12, Folic Acid - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Mundipharma K.K. | 25 | 2014-03-01 | 2017-11-09 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma Gemcitabine, Dexamethasone, Cisplatin - Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Canadian Cancer Trials Group | 21 | 2013-10-01 | 2026-03-27 |
| Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Belinostat, CHOP - Peripheral T-cell Lymphoma | Phase 1 | Completed | Acrotech Biopharma Inc. | 23 | 2013-05-01 | 2020-01-03 |
| Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies TGR-1202 - Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | TG Therapeutics, Inc. | 90 | 2013-01-07 | 2021-08-23 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea SP-02L (darinaparsin for injection) - Peripheral T-cell Lymphoma | Phase 1 | Completed | Solasia Pharma K.K. | 6 | 2012-09-01 | 2014-09-04 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Phase 1 | Completed | Robert Lowsky | 16 | 2012-01-01 | 2023-11-22 |
| A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) SP-02L (darinaparsin for injection) - Peripheral T-cell Lymphoma | Phase 1 | Completed | Solasia Pharma K.K. | 17 | 2011-09-01 | 2015-08-13 |
| E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma denileukin diftitox (E7777) - Peripheral T-Cell Lymphoma | Phase 1 | Completed | Eisai Co., Ltd. | 13 | 2011-07-01 | 2018-11-23 |
| Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma carfilzomib - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | University of Nebraska | 15 | 2011-06-21 | 2023-09-15 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 20 | 2011-05-01 | 2015-08-13 |
Showing 20 of 33. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (33) · Lymphoma, Extranodal NK-T-Cell (15) · Lymphoma, B-Cell, Marginal Zone (14) · Lymphoma, Follicular (14) · Lymphoma, Large B-Cell, Diffuse (14) · Lymphoma, Large-Cell, Anaplastic (14) · Lymphoma, Mantle-Cell (14) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (14) · Hodgkin Disease (13) · Immunoblastic Lymphadenopathy (13) · Lymphoma, Non-Hodgkin (13) · Lymphoma, T-Cell, Cutaneous (13) · Mycosis Fungoides (13) · Sezary Syndrome (13) · Waldenstrom Macroglobulinemia (13)
Hemic and Lymphatic Diseases (33) · Immune System Diseases (33) · Immunoproliferative Disorders (33) · Lymphatic Diseases (32) · Lymphoproliferative Disorders (32) · Neoplasms (32) · Neoplasms by Histologic Type (32) · Lymphoma, T-Cell (30) · Lymphoma (28) · Hematologic Diseases (22) · Leukemia, Lymphoid (20) · Lymphoma, Non-Hodgkin (20) · Leukemia (19) · Lymphoma, B-Cell (15) · Disease Attributes (14)
fludarabine phosphate (4) · Cyclophosphamide (3) · Lenalidomide (3) · romidepsin (3) · 10-propargyl-10-deazaaminopterin (2) · Azacitidine (2) · Carboplatin (2) · Cyclosporine (2) · Dexamethasone (2) · Doxorubicin (2) · Etoposide (2) · Folic Acid (2) · Gemcitabine (2) · Injections (2) · Mycophenolic Acid (2)
National Cancer Institute (NCI) (4) · Acrotech Biopharma Inc. (2) · Fred Hutchinson Cancer Center (2) · Massachusetts General Hospital (2) · Solasia Pharma K.K. (2) · AbbVie (prior sponsor, Abbott) (1) · Aileron Therapeutics, Inc. (1) · Amir Mortazavi (1) · Canadian Cancer Trials Group (1) · Case Comprehensive Cancer Center (1) · Celgene (1) · Chipscreen Biosciences, Ltd. (1) · City of Hope Medical Center (1) · Eisai Co., Ltd. (1) · Kyowa Kirin Co., Ltd. (1)
United States (25) · Japan (4) · Canada (3) · Italy (2) · Australia (1) · China (1) · Germany (1) · Singapore (1) · South Korea (1)
Jeremy Abramson, MD (2) · Amir Mortazavi, MD (1) · Anthony J Reiman (1) · Brenda Sandmaier (1) · Craig Reeder, M.D. (1) · David Hong (1) · David Maloney (1) · Hiroya Asou, MD (1) · Howard Burris, MD, FACP (1) · John Deeken (1) · Jonathan Brammer, MD (1) · Julie M Vose (1) · Kensei Tobinai, MD,PhD (1) · Kerry J Savage (1) · Mack Mabry, MD (1)
PMID 32499241, PMID 33051668, PMID 22259028, PMID 24474568, PMID 25605368, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28771889, PMID 29292843, PMID 29363235, PMID 29475723, PMID 29572391, PMID 30301414, PMID 30562587, PMID 31388792, PMID 33236943, PMID 33492438, PMID 33602316, PMID 34230007, PMID 41779512
P30CA015704 (2), P01CA018029 (1), P01CA078902 (1), P30CA012197 (1), P30CA016058 (1), P30CA016672 (1), P30CA036727 (1), P50CA136411 (1), U01CA062461 (1), U01CA097452 (1), U01CA121947 (1), U01CA132194 (1)